Janssen COVID-19 Vaccine

1 dose

Janssen Pharmaceuticals, it was shown to be 66% protective against moderate to severe Covid infection in a multi-country study. Importantly, it was 85% effective in protecting against severe disease.

How to Clean and Disinfect Your Home if Someone has COVID-19

General information

Name: Janssen COVID-19 Vaccine
Manufacturer: Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Vaccine type: Adenovirus
Number of doses: 1 dose
Mode of administration: injection into the muscle of the upper arm
Does not contain: Preservatives.

Who should get vaccinated?

J&J’s vaccine has been authorized for individuals 18 years of age and older.

Who should not get vaccinated?

You should not get the Janssen COVID-19 Vaccine if you had a severe allergic reaction to any ingredient of this vaccine.

Side effects and safety

In the arm where you received the injectable vaccine:

  • Pain
  • Swelling
  • Redness

In the rest of the body:

  • Fever
  • Muscle aches
  • Nausea
  • Fatigue
  • Headache

There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination.

Information on the effectiveness of the vaccine

Among these participants, 19,630 received the vaccine and 19,691 received placebo. Overall, among these clinical trial participants, the vaccine was approximately 67% effective in preventing moderate to severe/critical COVID-19 disease occurring at least 14 days after vaccination and 66% effective in preventing moderate to severe/critical disease at least 28 days after vaccination.

Additionally, the vaccine was approximately 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

Demographic information from clinical trials

An ongoing, multicenter, randomized, double-blind, placebo-controlled Phase 3 Study (COV3001) (NCT04505722) is being conducted in the United States, South Africa, Brazil, Chile, Argentina, Colombia, Peru and Mexico to assess the efficacy, safety, and immunogenicity of a single-dose of the Janssen COVID-19 Vaccine for the prevention of COVID-19 in adults aged 18 years and older:

  • 58,7 % white
  • 45,3 % Hispanic/Latino
  • 19,4 % African American
  • 9,5% American Indian or Alaska Native
  • 3,3 % Asian
  • 0,2 % Native Hawaiian or other Pacific Islander
  • < 5,6 % of people of other races / ethnicities

Breakdown by age and sex:

  • 54,9 % men
  • 45,0 % women
  • 19,5 % 65 years of age or older​

Johnson & Johnson’s Janssen COVID-19 Vaccine Overview and Safety

CDC and FDA have recommended that use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, effective April 23, 2021. However, women younger than 50 years old especially should be aware of the rare risk of blood clots with low platelets after vaccination, and that other COVID-19 vaccines are available where this risk has not been seen.

Read more FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine